Back to News
Market Impact: 0.35
Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
Source: gurufocus.com
Healthcare & BiotechCompany Fundamentals
Johnson & Johnson said ERLEADA (apalutamide) given before and after surgery reduced the risk of recurrence or death by 62% versus surgery alone in high-risk patients. The provided article text is truncated, so it does not specify the patient population further, the study period, or absolute risk reduction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.55
Ticker Sentiment
JNJ0.80
More News
- J&J prostate cancer drug shows promising tumor responses in early trial
- Johnson & Johnson announces ERLEADA® (apalutamide) treatment before and after surgery reduces risk of recurrence or death by 62% versus surgery alone in high-risk prostate cancer
- AI funding fears rattle Wall Street. Here's how we're adjusting our portfolio
- Nvidia's role as AI financier faces first big test as neoclouds take market hit
- Here’s the ‘core economic flaw’ in the AI bull case as stock and bond trades unravel, according to a top economist
- Trump set to announce plan by Audi to build a U.S. factory in Georgia, source says
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Best AI Stock Research Tools for Professional Investors
- Weekly Update: Adding Live MBO Level 3 Data - Liquidity Heatmap, OFI Charts, and More